SecBot SecBot

EVMN

Evommune, Inc.
NYSE· Pharmaceutical Preparations· Inc. DE· CIK 0002044725 Biotech & Drug Discovery
$5.16 +0.03 (+0.58%)
Oct 27 4:00 PM ET · prev $5.13
Market cap
$185.1M
Micro cap
Consensus
Buy
83% Buy or better · 18 analysts
Median target
$22.00
+326% · range $8.00–30.00
1 year
−74.5%
from $20.23 · Nov 6
30 days
−38.5%
from $8.39
52-week range
$5.10–31.57
−84% from high · low Oct 23
Avg volume 20D
820.2K
Oct 7 spike 2.11M
Short interest
3.53M
≈9.7% of shares · +22.1%
Days to cover
3.4
at average volume
Insider net
−$2.1M
2 buyers · 6 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 1 exit
Filing reports
15
analyzed by SecBot
SecBot read BULLISH 3 reports · 90 days
Balance 0 bearish · 1 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 3/3
Strongest BULLISH Evommune presented late-breaking Phase 2a proof-of-concept data for EVO301 in atopic dermatitis at the EADV…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders bought $146.3K at an average $13.30. 6 insiders sold $2.3M. Price is 61% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 21 added (0 new), 5 trimmed or exited.

  • AnalystsBULLISH

    15 of 18 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.746 → −$0.835 over 90 days. 1 up, 5 down in 30 days.

  • Short sellersBUILDING

    Short interest +22.1% to 3.53M shares. 3.4 days to cover, ≈9.7% of shares.

  • TrendDOWNTREND

    44% below its 50-day average. New closing low $5.10 on Oct 23.

Who's buying

13F· Q2 2026
0
new positions
1
exit
FundMoveSharesValue
PRICE T ROWE ASSOCIATES INC /MD/ADD1,940,939$25.8M
Point72 Asset Management, L.P.DOUBLED1,435,049$19.1M
BlackRock, Inc.ADD886,538$11.8M
VANGUARD CAPITAL MANAGEMENT LLCADD881,895$11.7M
AMERICAN CENTURY COMPANIES INCADD755,018$10.0M
UBS Group AGADD413,553$5.5M
STATE STREET CORPADD293,516$3.9M
MORGAN STANLEYDOUBLED290,174$3.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts
Buy 83% rate it Buy or better
Strong Buy5Buy10Hold3Sell0Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +326%.Targets as of Oct 28, 2026.

Recent actions
DateFirmActionRating
Oct 12, 2026UBS
INITIATE
INITIATENeutral
Sep 9, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
Sep 9, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Sep 9, 2026HC Wainwright & Co.
REITERATE
REITERATENeutral
Aug 26, 2026Needham
INITIATE
INITIATEBuy
Aug 7, 2026RBC Capital
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$146.3K
bought · 2 insiders
$2.3M
sold · 6 insiders
−61.2%
vs their $13.30 cost
DateInsiderTypeValue
Sep 30, 2026
Pena Luis C.
President & CEO
AWARD$7.8K
Jul 8, 2026
Carver Kyle
Chief Financial Officer
BUY$13.3K
Jul 7, 2026
KIRSCH ARTHUR S
Director
BUY$133.0K
Jun 22, 2026
Pena Luis C.
President & CEO
SELL$168.9K
Jun 22, 2026
Patel Jeegar Pravinkumar
Chief Scientific Officer
EXERCISE$5.7K
Jun 22, 2026
Drew Janice Suzann
Chief of Dev. Operations
SELL$452.6K
Jun 22, 2026
Drew Janice Suzann
Chief of Dev. Operations
EXERCISE$14.7K
Jun 22, 2026
Patel Jeegar Pravinkumar
Chief Scientific Officer
SELL$33.5K

Earnings setup

Estimates
−$0.83
EPS estimate, this quarter
−12%
estimate change, 90 days
1↑ 5↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.83-$1.02–-$0.67+0.4%$0.00
Next Q-$0.92-$1.14–-$0.66+0.1%$0.00
Current FY-$3.48-$5.53–-$2.87-0.0%$0.00
Next FY-$3.56-$4.37–-$2.22-0.9%$250.0K

Short side

FINRA· Oct 15, 2026
3,533,042
shares short
+22.1%
vs prior settlement
3.4
days to cover
≈9.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 Short interest report
Short Interest: EVMN up 22% to 3.5M shares
Settlement 2026-10-15 | Days to cover: 3.42 | ≈9.74% of shares outstanding (est.)
Oct 1, 2026 SEC
Evommune presented late-breaking Phase 2a proof-of-concept data for EVO301 in atopic dermatitis at the EADV 2026…
8-K — Impact 7/10
Sep 30, 2026 Insider
Pena Luis C. was granted 1,115 shares
President & CEO @ $7.02 ($7.8K)
Sep 15, 2026 SEC
Evommune posted an updated corporate presentation on its website via an 8-K (Item 7.01). The presentation highlights…
8-K — Impact 4/10
Jul 30, 2026 SEC
Evommune announced initiation of a Phase 2b clinical trial for EVO756, an oral MRGPRX2 antagonist, for migraine…
8-K — Impact 5/10
Jul 8, 2026 Insider
Carver Kyle bought 1,000 shares
Chief Financial Officer @ $13.26 ($13.3K)
Jul 7, 2026 Insider
KIRSCH ARTHUR S bought 10,000 shares
Director @ $13.30 ($133.0K)
Jun 30, 2026 Inst.
PRICE T ROWE ASSOCIATES — ADD
1,940,939 shares ($25.8M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 15, 2026
Short interest
Short Interest: EVMN up 22% to 3.5M shares
Settlement 2026-10-15 | Days to cover: 3.42 | ≈9.74% of shares outstanding (est.)
Oct 2, 2026
Trial readout
Results Pending: EVO756 (Phase 2) — Completed 71d ago
Trial: Phase 2b Study of EVO756 in Adults With Atopic Dermatitis Sponsor: Evommune, Inc. Phase: Phase 2 | Completed: 2026-07-23 Conditions: Atoptic…
Sep 15, 2026
Short interest
Short Interest: EVMN down 34% to 2.9M shares
Settlement 2026-09-15 | Days to cover: 3.32 | ≈7.93% of shares outstanding (est.)
Aug 25, 2026
Trial readout
Results Pending: EVO756 (Phase 2) — Completed 88d ago
Trial: Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU) Sponsor: Evommune, Inc. Phase: Phase 2 |…
Aug 11, 2026
Trial readout
Results Pending: EVO756 (Phase 2) — Completed 74d ago
Trial: Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU) Sponsor: Evommune, Inc. Phase: Phase 2 |…

SecBot reports

15 filings · 2 bullish · 3 bearish · 10 neutral
All EVMN filing & press-release reports (15)